Explore evidence

4 %Phylogenetic analysis of the gp41 region of 123 HIV-1-seropositive specimens from Cameroon showed that 5 (4%) were subtype F.

CamerounVIH/sidapublished 2000AIDS Research and Human RetrovirusesOpenAlexdocument of 7 observations

22.5 %Twenty-two point five percent of the 142 strains had two mutations in the protease gene.

CamerounVIH/sidapublished 2000Journal of Clinical MicrobiologyOpenAlexdocument of 19 observations

24 sequencesAmong 39 subtype A sequences in Cameroon, 24 (61.5%) formed a distinct subcluster with the AG-IBNG prototype strain.

CamerounVIH/sidapublished 2000JAIDS Journal of Acquired Immune Deficiency SyndromesOpenAlexdocument of 6 observations

13.5 %Pretreatment HIV drug resistance (PDR) prevalence among ART initiators with no prior exposure to antiretrovirals in urban areas of Cameroon was 13.5% (95% CI 5.1%–31.5%).

CamerounVIH/sidaobserved 2015published 2018The Journal of antimicrobial chemotherapyeurope_pmcdocument of 12 observationsDOI 10.1093/jac/dky221

3.6 %HIV prevalence among men Armed Forces personnel of the Democratic Republic of Congo stationed in Kinshasa was 3.6% between June and September 2007.

CamerounVIH/sidaobserved June and September 2007published 2015International journal of STD & AIDSeurope_pmcdocument of 6 observations

18 %Among HIV-1 protease (PR) sequences from drug-naïve Cameroonians, the secondary PI resistance-associated mutation 63P was present in 18% of strains.

CamerounVIH/sidapublished 2002Journal of Clinical MicrobiologyOpenAlexdocument of 12 observations

89 %The prevalence of the 356K substitution in reverse transcriptase sequences was 89% among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublished 2011AIDS Research and Human RetrovirusesOpenAlexdocument of 24 observations

60 %In West Africa, most probably between 60% and 84% of subtype A viruses are recombinant AG-IBNG viruses.

CamerounVIH/sidapublished 2000JAIDS Journal of Acquired Immune Deficiency SyndromesOpenAlexdocument of 6 observations

87.7 %Among patients with VL ≥ 1000 copies/ml, HIV drug resistance was identified in 87.7% of ART 48-60 patients.

CamerounVIH/sidapublished 2018EClinicalMedicineeurope_pmcdocument of 6 observations

10.4 %Pretreatment HIV drug resistance (PDR) prevalence among all ART initiators in Cameroon was 10.4% (95% CI 5.4%–19.1%).

CamerounVIH/sidaobserved 2015published 2018The Journal of antimicrobial chemotherapyeurope_pmcdocument of 12 observationsDOI 10.1093/jac/dky221

88.5 %88.5% of participants were on antiretroviral treatment.

CamerounVIH/sidapublished 2017Tropical diseases, travel medicine and vaccineseurope_pmcdocument of 8 observations

94.1 %Overall, sensitivities of the evaluated HIV diagnostic tests ranged between 94.1% and 100%.

CamerounVIH/sidapublished 2009PloS oneeurope_pmcdocument of 6 observations

Sub-Saharan Africa has the highest burden of HIV in the world.

CamerounVIH/sidapublished 2013International journal of epidemiologyeurope_pmcdocument of 10 observationsDOI 10.1093/ije/dyt198

22.5 %HIV seroprevalence in young women in southern Cameroon is 22.5%.

CamerounVIH/sidapublished 2007Emerging infectious diseasesOpenAlexdocument of 7 observationsDOI 10.3201/eid1303.061069

99 %Among HIV-1 protease (PR) sequences from drug-naïve Cameroonians, the secondary PI resistance-associated mutation 36I was present in 99% of strains.

CamerounVIH/sidapublished 2002Journal of Clinical MicrobiologyOpenAlexdocument of 12 observations

9.8 %Nine point eight percent of the 142 strains had three mutations in the protease gene.

CamerounVIH/sidapublished 2000Journal of Clinical MicrobiologyOpenAlexdocument of 19 observations

100 %Follow-up with referral facilities showed 100% of patients (defaulters and newly enrolled) linked to care were enrolled at a facility.

CamerounVIH/sidapublished 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations

1 log10_HIV_RNA_copies_per_mlVersion 1.5 yielded a significant increase in viral load for samples infected with subtypes A and E (greater than 1 log10 HIV RNA copies/ml).

CamerounVIH/sidapublished 1999Journal of Clinical MicrobiologyOpenAlexdocument of 6 observationsDOI 10.1128/jcm.37.1.110-116.1999

Total cholesterol was significantly increased with duration of highly active antiretroviral therapy (HAART) in HIV-infected Cameroonians.

CamerounVIH/sidapublished 2013Diabetes & metabolismeurope_pmcdocument of 12 observations

135 cells/mm³The median baseline CD4 count among 169 HIV-1-infected patients was 135 cells/mm³.

CamerounVIH/sidapublished 2010BMC Public HealthOpenAlexdocument of 6 observationsDOI 10.1186/1471-2458-10-105

29 reference strainsCultured virus from 29 HIV-1 reference strains was tested, including 3 of subtype A, 6 of subtype B, 5 of subtype C, 3 of subtype D, 8 of subtype E, 3 of subtype F, and 1 of subtype G.

CamerounVIH/sidapublished 1999Journal of Clinical MicrobiologyOpenAlexdocument of 6 observationsDOI 10.1128/jcm.37.1.110-116.1999

27.4 %La prévalence de la neuropathie chez les personnes vivant avec le VIH au Cameroun était de 27,4 % en 2015.

CamerounVIH/sidaobserved 2015HAL · Unilimdocument of 747 observations

14.7 %Pretreatment HIV drug resistance (PDR) frequency was 14.7% in Vietnam.

CamerounVIH/sidapublished 2018Journal of Antimicrobial ChemotherapyOpenAlexdocument of 9 observationsDOI 10.1093/jac/dky443

72 %Seventy-two percent of the recruited HIV-infected Cameroonians were women.

CamerounVIH/sidapublished 2013Diabetes & metabolismeurope_pmcdocument of 12 observations

150 cells_per_mm3At baseline, the median CD4 cell count was 150/mm3.

CamerounVIH/sidaobserved baselinepublished 2005Antiviral TherapyOpenAlexdocument of 8 observationsDOI 10.1177/135965350501000208